APAC IPOs & Placements, Aequitas Research

Nicholas Tan

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/pharmaron-beijing-co-ltd-a8e38476-30ac-461e-9c7d-16ba5f06f997" target="_blank" data-smartkarma-citation="entities:28277:1" rel="noopener">Pharmaron Beijing (300759 CH)</a> is looking to raise US$175m in its primary offering. </li>
<li>The company plans to use the proceeds for project development, repayment of bank loans and as working capital.</li>
<li>In this note, we will talk about the placement and run the deal through our ECM framework.</li>
</ul>



Pharmaron Beijing (300759 CH) is looking to raise US$175m in its primary offering. 
The company plans to use the proceeds for project development, repayment of bank loans and as working capital.
In this note, we will talk about the placement and run the deal through our ECM framework.


Pharmaron Beijing Placement: Shares Had a Good Start This Year